On the following pages, you will find extensive information about AlzChem Group AG. We present to you both the company’s Management Board and the Supervisory Board. In addition, relevant financial figures can be accessed here.
Vertically integrated producer of a portfolio of diverse chemical products based on the calcium carbide / calcium cyanamide chain with strategic focus on growth of its Specialty Chemicals segment
Leading market positions in selected niche markets
R&D focus on developing products supported by megatrends
Integrated manufacturing system (“Verbund System”) allows for flexible dealing with changes of demand in diversified end markets
Headquartered in Germany, global sales and distribution network
Four production facilities in Germany, one in Sweden
Ulli Seibel, CEO
Ulli Seibel was born in Landau in 1975. After studying industrial engineering (Wirtschaftsingenieurwesen) in Karlsruhe, he began his career as Assistant to the Management Board of Fundatio AG. He worked for Arques Industries AG between 2005 and 2009, ultimately as Vice President of Operations. Ulli Seibel has been Managing Director of AlzChem Trostberg GmbH since 2009. He has also served as CEO of AlzChem Group AG since AlzChem Trostberg GmbH was incorporated into the listed Group in October 2017.
Andreas Niedermaier, CFO
Andreas Niedermaier was born in Tittmoning in 1969. After studying industrial engineering in Rosenheim, he began his career as Consultant for Cost Calculators and Controllers at Kettner Maschinenbau GmbH. He worked as Controller for Vinnolit GmbH & Co. KG in Gendorf and Burghausen from 1997 to 1999, where he was responsible for production facility controlling. Andreas Niedermaier has been with AlzChem and its predecessors since 1999. He has served as Managing Director of AlzChem Trostberg GmbH since 2010 and also as also CFO of AlzChem Group AG since AlzChem Trostberg GmbH was incorporated into the listed Group in October 2017.
Klaus Dieter Englmaier, COO
Klaus Dieter Englmaier was born in Trostberg in 1960. After studying mechanical engineering in Munich, he began his career in the Operations Planning department of Wacker Chemie GmbH in Burghausen in 1985. Klaus Dieter Englmaier has worked for AlzChem and its predecessors since 1988, initially as Plant Manager for calcium cyanamide production. He directed AlzChem’s production and technology as Vice President from 2006 to 2016. He also directed the chemical parks in Trostberg and Hart from 2010 to 2016. Klaus Englmaier has been a member of the Management Board of AlzChem Trostberg GmbH since 2016. He has also served on the Management Board of AlzChem Group AG since AlzChem Trostberg GmbH was incorporated into the listed Group in October 2017.
Markus Zöllner (Chairman)
Markus Zöllner was born in Straubing in 1968. He has studied industrial engineering (FH) (Wirtschaftsingenieurwesen) in Rosenheim. After his studies, he started his career as an engineer at Mannesmann Mobilfunk GmbH in 1993. In 2000, he obtained an MBA degree (WHU-Kellogg). In 2002, he was appointed Managing Director (Geschäftsführer) of Tesion Telekommunikation GmbH. In 2003, he was appointed Managing Director of Versatel Deutschland GmbH where he acted as CFO. From 2005 until 2007, Markus Zöllner was a member of the Management Board (Vorstand) of Arques Industries AG. He has been serving as Chairman of the Supervisory Board of AlzChem AG since 2016 and of AlzChem Group AG since 2017. He is also the Managing Director of his own investment company four two na GmbH.
Prof. Dr. Martina Heigl-Murauer
Prof. Dr. Martina Heigl-Murauer was born in Deggendorf in 1967. She studied business administration (Betriebswirtschaftslehre) in Rosenheim until 1994. After her studies, she started her career as an associate at Steuerberater- und Wirtschaftsprüfunggesellschaft Dr. Kittl & Partner and became a tax consultant. Following her PhD studies in international tax law from 2005 until 2009 in Bratislava, Slovakia, Prof. Dr. Martina Heigl-Murauer was appointed professor at the University of Applied Sciences in Deggendorf. In 2012, she became a member of the senate of the University of Applied Sciences in Deggendorf and has been chairwoman since 2013. Until 2015, she worked as a self-employed tax consultant in Landshut. Since 2015, Prof. Dr. Martina Heigl-Murauer has worked as a tax consultant for Ecovis BLB Steuerberatungsgesellschaft. Since 2016, she has been a member of the Supervisory Board at AlzChem AG and since 2017 at AlzChem Group AG.
Dr. Caspar Freiherr von Schnurbein
Dr. Caspar Freiherr von Schnurbein was born in 1973 in Augsburg. He studied law at the universities of Würzburg, Coimbra (Portugal) and Munich, where he passed his first and second legal state exam. Following his PhD studies in stock corporation law, he started his career as corporate and M&A lawyer in the Munich office of an international law firm. Dr. Caspar Freiherr von Schnurbein is currently General Counsel of LIVIA Corporate Development SE where he is responsible for all legal matters. He has been a member of the Supervisory Board of AlzChem Trostberg GmbH since 2016 and of AlzChem Group AG since August 2017.
Steve Röper was born in 1976 in Waren (Müritz). He studied law at the University of Rostock and passed his second legal state exam in Munich. From 2004 to 2007, he worked as an attorney at Heussen Rechtsanwaltsgesellschaft in Munich, as part of the corporate and commercial law team. From 2007 to 2009, he worked for KraussMaffei Group, Munich, where he served as senior counsel for the extrusion division. In 2009, he joined Luxembourg-based private equity fund bluO as general counsel. Since 2013, he has worked as a self-employed attorney in Munich. In 2009, he became a member of the Supervisory Board at AlzChem Trostberg GmbH. He has also been a member of the Supervisory Board of AlzChem Group AG since October 2017.
|Net sales (EUR mn)||322.6||327.2||353.9||375.2|
|EBITDA (EUR mn)||33.2||38.6||45.7||49.4|
|Adjusted EBITDA (EUR mn)**||-||44.9||47.7||-|
|Adjusted EBITDA margin**||-||13.7%||13.5%||-|
|CF from operating activities (EUR mn)||28.2||33.1||30.7||34.7|
* Unaudited; calculated by adding the two short fiscal years
**Adjusted for non-recurring costs in connection with the IPO